Suven Life Sciences Ltd. (BSE: 530239) is a Hyderabad, Telangana-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹7,951 Cr, it ranks #666 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 10 in Life Sciences Tools and Services. At ₹277.90 (as of 19 Nov 2026), the share price is 31.1% below its 52-week high of ₹403.35 and 123.9% above its 52-week low of ₹124.11. The share price is up 51.8% over one year and down 16.6% over three months.
| Current Price | ₹277.90 |
|---|---|
| Market Cap | ₹7,951 Cr |
| BSE Code | 530239 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -78.80% |
| Return on Assets | -47.69% |
| 52-Week Range | ₹124.11 – ₹403.35 |
| 1-Year Price Change | +51.8% |
| 3-Month Price Change | -16.6% |
| Beta (1Y) | 0.84 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.suven.com |
| Revenue | ₹1 Cr |
|---|---|
| Net Profit | ₹-107 Cr |
| Net Margin | -8911.7% |
| EPS (Basic) | ₹-3.77 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Suven Life Sciences Ltd. reported revenue of ₹1 Cr in Q2 FY27, up 30.4% from ₹1 Cr in Q2 FY26 and down 66.4% from ₹4 Cr in Q1 FY27. It posted a net loss of ₹107 Cr for the quarter, against a net loss of ₹77 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1 Cr (Q2 FY26) to ₹4 Cr (Q1 FY27). The company reported a net loss in 7 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1 Cr | −₹107 Cr | −8911.7% |
| Q1 FY27 | ₹4 Cr | −₹128 Cr | −3574.5% |
| Q4 FY26 | ₹2 Cr | −₹46 Cr | −3000.0% |
| Q3 FY26 | ₹3 Cr | −₹102 Cr | −3627.0% |
| Q2 FY26 | ₹1 Cr | −₹77 Cr | −8403.3% |
| Q1 FY26 | ₹2 Cr | −₹52 Cr | −2755.1% |
| Q4 FY25 | ₹1 Cr | −₹44 Cr | −2989.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 65.47% of Suven Life Sciences Ltd.'s shares as of Sept 2026, against 67.36% in Dec 2025 (−1.89 percentage points). Delivery averaged 39.9% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D
1. Research and Development Services-This segment provides a range of drug discovery and development support services to pharma and biotech companies. 2. Manufacturing (CRAMS)-This segment develops and produces bulk drugs and intermediates under contract manufacturing services. 3. Services (DDDSS)-This segment offers clinical trials, testing, and analysis services, as well as engages in the collaborative research projects. 4. Unallocated-0
1. Research and Development Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,840 Cr | 40.2 | 13.94% | ₹1,122 Cr | +26.1% |
| Suven Life Sciences Ltd. | ₹7,951 Cr | n/m | -78.80% | ₹1 Cr | +51.8% |
| Vimta Labs Ltd | ₹2,259 Cr | 29.5 | 18.55% | ₹112 Cr | -26.8% |
| Tarsons Products Limited | ₹1,730 Cr | 114.9 | 2.26% | ₹124 Cr | +25.7% |
| Brooks Laboratories Ltd. | ₹198 Cr | 7.9 | 22.28% | ₹19 Cr | -34.2% |
| Bilcare Ltd. | ₹194 Cr | 108.3 | -5.21% | — | — |
| Jeevan Scientific Technology Ltd | ₹176 Cr | 129.4 | 1.68% | — | +42.3% |
| Vivo Bio Tech Ltd. | ₹37 Cr | n/m | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹26 Cr | n/m | -68.79% | — | -45.3% |
Listed by market capitalisation. Ratios are shown for context only.
Suven Life Sciences Ltd. is trading at ₹277.90, with a market capitalisation of ₹7,951 Cr.
Suven Life Sciences Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Suven Life Sciences Ltd. has a return on equity of -78.80%.
Suven Life Sciences Ltd. is listed on the BSE under the scrip code 530239.
Suven Life Sciences Ltd.'s share price is up 51.8% over one year and down 16.6% over three months. Its 52-week range is ₹124.11 to ₹403.35.
In Q2 FY27, Suven Life Sciences Ltd. reported revenue of ₹1 Cr and net profit of ₹-107 Cr, with basic EPS of ₹-3.77 (consolidated, parsed from the company's exchange filing).
Suven Life Sciences Ltd. reported revenue of ₹1 Cr in Q2 FY27, up 30.4% from ₹1 Cr in Q2 FY26 and down 66.4% from ₹4 Cr in Q1 FY27.
Promoters held 65.47% of Suven Life Sciences Ltd.'s shares as of Sept 2026, against 67.36% in Dec 2025 (−1.89 percentage points).
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.